Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …

Background There are no head-to-head randomized controlled trials comparing different
direct oral anticoagulants (DOACs). Thus, we systematically reviewed and meta-analyzed …

New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been
developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients …

We performed a meta-analysis of data on the effectiveness and safety of apixaban
compared with other oral anticoagulants (warfarin or rivaroxaban or dabigatran or …

Atrial fibrillation (AF), a common arrhythmia, increases the risk of ischemic stroke. Stroke and
bleeding scores for patients with AF can help to stratify risk and determine the need for …

Methods Databases were searched for randomized warfarin-controlled trials of novel
anticoagulants for non-valvular atrial fibrillation. The primary end-point was long-term …

Background This study was designed to compare efficacy and safety among novel oral
anticoagulants (NOACs), which have not been directly compared in randomized control …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …

Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …